The use of medicines during pregnancy is a growing public health concern due to the risk of developmental toxicity. Healthcare providers heavily rely on the FDA pregnancy risk categories (A, B, C, D,
The ability of drugs to induce phospholipidosis (PLD) is linked directly to their molecular substructures: hydrophobic, cyclic moieties with hydrophilic, peripheral amine groups. These structural prop
Drug-Induced-Liver-Injury (DILI) is a leading cause of termination in drug development programs and removal of drugs from the market because of inability to identify potential patients prior to clinic
